intervalo乳腺癌检测对HER2阳性pT1a N0M0乳腺癌预后影响
基于意大利Emilia-Romagna地区2003-2009年874例pT1a N0M0乳腺癌患者的多中心人群登记研究,分析interval cancer(IC)与screen-detected(SD)癌症中HER2阳性者的预后差异。中位随访115个月,HER2阳性IC的10年iDFS为75.0%,显著低于HER2阳性SD的93.8%,交互作用HR=5.3。结论提示IC检测可能识别出HER2阳性pT1a N0M0中复发风险较高、值得考虑抗HER2辅助治疗的患者。
要点
- HER2阳性IC的10年iDFS为75.0%,低于HER2阳性SD的93.8%。
- IC与HER2阳性状态对较差iDFS存在交互作用,校正后HR=5.3。
- IC检测可能识别HER2阳性pT1a N0M0中需考虑抗HER2辅助治疗者。
核心结论
- 在pT1a N0M0乳腺癌中,HER2阳性IC的10年iDFS低于HER2阳性SD癌症,交互作用分析支持IC检测可识别复发风险较高、值得考虑常规抗HER2辅助治疗的患者。
研究设计与样本
- 多中心基于人群的癌症登记研究,纳入意大利Emilia-Romagna地区2003至2009年诊断的50-69岁女性所有 incident pT1a N0M0乳腺癌(n=874)。
- 排除未暴露于筛查、HER2状态未知和/或接受辅助曲妥珠单抗治疗的患者。
主要发现
- 组织学高级别、激素受体阴性或HER2阳性(OR=1.7;95%CI:1.1-2.7)的乳腺癌更可能是IC。
- 中位随访115个月,HER2阳性IC的10年iDFS为75.0%(95%CI:55.5%-94.5%),HER2阳性SD为93.8%(95%CI:86.5%-100%)。
- 校正预后变量后,IC与HER2阳性状态对较差iDFS存在交互作用(HR=5.3;95%CI:1.6-16.7)。
临床怎么用
- 对于HER2阳性pT1a N0M0乳腺癌,IC检测状态可能有助于识别复发风险较高、需考虑常规抗HER2辅助治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although human epidermal growth factor receptor 2 (HER2) overexpression is associated with poor prognosis, patients (pts) with pT1a N0M0 breast cancers (BCs) have an excellent outcome across all subtypes. Interval cancers (ICs) have poorer survival than screen-detected (SD) tumours, and an association has been reported between ICs and HER2 overexpression. We aimed to determine, in a general population of pT1a N0M0 BCs with known screening status, whether HER2-positive ICs have a poorer outcome than HER2-positive SD cancers. METHODS: We evaluated all incident pT1a N0M0 BCs (n = 874) collected in the Emilia-Romagna region (Italy) from 2003 to 2009 and diagnosed in women aged 50-69. Pts unexposed to screening, with unknown HER2 status and/or treated with adjuvant trastuzumab were excluded from analysis. RESULTS: Sixty-one percent of the BCs were SD, whereas 19% were ICs. BCs with high histologic grade, hormone receptor-negative or HER2-positive status (odds ratio=1.7; 95% confidence interval [CI]: 1.1-2.7) were more likely ICs. Median follow-up was 115 months. The 10-year invasive disease-free survival (iDFS) for HER2-positive ICs was lower than that for HER2-positive SD cancers: 75.0% (95% CI: 55.5%-94.5%) versus 93.8% (95% CI: 86.5%-100%). An interaction between ICs and HER2-positive status was found for poorer iDFS after adjusting for prognostic variables (HR = 5.3; 95% CI: 1.6-16.7). CONCLUSIONS: IC detection may identify pts with HER2-positive pT1a N0M0 tumours in whom the rate of recurrence justifies consideration for conventional, anti-HER2, adjuvant treatment.
引用
- Musolino A, Falcini F, Sikokis A, et al. Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study. Eur J Cancer. 2017. PMID: 29175735. doi:10.1016/j.ejca.2017.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。